Kineta Invited to Participate at the BIO CEO & Investor Conference
Feb 5, 2020
SEATTLE, Feb. 5, 2020 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at the BIO CEO & Investor Conference. Craig W. Philips, President, will provide a corporate overview at the conference which is being held February 10-11 at the Marriott Marquis in New York. Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.
Presentation Details
Date: Tuesday, February 11th
Time: 10:00 AM, Eastern Time
Location: New York Marriott Marquis
Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in innate immunity and immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's and its affiliates' plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's and its subsidiaries' businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither Kineta nor its affiliates undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact:
Jacques Bouchy
[email protected]
(206) 378-0400
SOURCE Kineta, Inc.
Related Links
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.